UK Firm Launches Private AI for Healthcare Sector

OneAdvanced introduces a secure Artificial Intelligence for healthcare industry needs.

A UK-based software company, OneAdvanced, has made a significant stride in the healthcare industry by launching a private sovereign Artificial Intelligence designed specifically for healthcare businesses. The advancements in technology aim to provide secure solutions catering to the unique needs of this sector.

The software, a Large Language Model (LLM), is engineered to support role-specific, organization-specific, and sector-specific functions within healthcare entities. This development represents a movement towards more secure and specialized applications of Artificial Intelligence, focusing on privacy and data protection in highly sensitive environments.

OneAdvanced´s initiative reflects a broader trend of employing Artificial Intelligence to enhance operational efficiencies and innovation within healthcare. By focusing on specialized AI models, the company aims to meet the growing demand for data-driven insights while maintaining rigorous security standards imperative in the healthcare industry.

65

Impact Score

Governance gaps emerge as agentic Artificial Intelligence scales

Agentic Artificial Intelligence is moving from assisted chatbots to autonomous workflows faster than enterprise governance is adapting. The shift raises accountability, security, lifecycle, and cost control challenges that organizations must address in operational code from the start.

Where OpenAI technology could appear in Iran

OpenAI’s Pentagon deal and defense partnerships could place its models in targeting workflows, drone defense systems, and military administration tied to the Iran conflict. The company’s role reflects a broader push to weave generative Artificial Intelligence into US military operations.

Artificial Intelligence tumour testing aims to personalize cancer treatment

A UK-funded cancer testing platform is using living tumour replicas and Artificial Intelligence analysis to identify which drugs are most likely to work before treatment starts. Researchers say the approach could reduce ineffective chemotherapy and improve decisions for patients with aggressive cancers.

Contact Us

Got questions? Use the form to contact us.

Contact Form

Clicking next sends a verification code to your email. After verifying, you can enter your message.